What does EMPA-Reg stand for?
What does EMPA-Reg stand for?
EMPA-REG OUTCOME. Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients. EMPA-REG RENAL. Efficacy and Safety of Empagliflozin in Patients With Type 2 diabetes and Renal Impairment.
What is the EMPA-Reg trial?
The EMPA-REG OUTCOME trial showed that empagliflozin is superior to placebo in improving glycemic control and reducing CV events including mortality in patients with DM2 and established CV disease.
What is the drug empagliflozin used for?
Empagliflozin is used to treat type 2 diabetes. It works in the kidneys to prevent absorption of glucose (blood sugar).
What is EMPA-Reg outcome?
EMPA-REG OUTCOME is an international, prospective, placebo-controlled clinical trial investigating the cardiovascular outcomes of empagliflozin, an inhibitor of sodium-glucose cotransporters type 2 (SGLT2), in patients with type 2 diabetes mellitus and known cardiovascular disease.
How much was the relative risk reduction of CV death in Empa Reg?
9 Furthermore, in patients with T2D and established atherosclerotic cardiovascular disease (ASCVD), the EMPA‐REG OUTCOME trial showed that, when added to standard of care, empagliflozin (compared with placebo) significantly reduced the risk of cardiovascular (CV) death by 38%, all‐cause mortality by 32%, and HHF by 35% …
How does Jardiance reduce CV risk?
— Animal study supports mechanism for glucose-independent effects. The SGLT2 inhibitor empagliflozin (Jardiance) shifted myocardial metabolism from glucose to other more energy-efficient metabolites in a pig model, researchers said, suggesting a mechanism for its cardiac benefits beyond glucose lowering.
How much weight can you lose on empagliflozin?
In a clinical study, people who took Jardiance alone or with other diabetes drugs lost between 1.8 percent and 3.2 percent of their body weight. This weight loss was seen over 24 weeks of treatment. In another clinical study, people who took Jardiance with metformin lost an average of 3.9 percent of their body weight.
Can you take linagliptin and empagliflozin together?
Empagliflozin and linagliptin combination is used together with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. It is also used to lower the risk of death in patients with type 2 diabetes and heart or blood vessel disease.
How safe is empagliflozin?
Empagliflozin is rated a safety category C in pregnancy.
When should empagliflozin be taken?
Empagliflozin comes as a tablet to take by mouth. It is usually taken once a day in the morning with or without food. Take empagliflozin at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.
How does Empagliflozin reduce heart failure?
Background: Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2) inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure events, and this action is particularly important in patients with fluid retention.
What does 3 point Mace mean?
The so-called “classical 3-point MACE” is defined as a composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death. But another study defines MACE as “CVD events, admission for HF (Heart Failure), ischemic cardiovascular [CV] events, cardiac death, or MACE”.
What is the supplemental appendix to the process investigators?
Supplementary Appendix. This appendix has been provided by the authors to give readers additional information about their work. Supplement to: The ProCESS Investigators. A randomized trial of protocol-based care for early septic shock.
Who funds the Empa-Reg outcome clinical trial?
(Funded by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676 .)
Which dose of empagliflozin should I take?
The empagliflozin dosage groups were pooled for the analysis of empagliflozin versus placebo; however, the hazard ratios were similar for 10 mg and 25 mg for primary outcomes. It is reasonable to assume that the choice of dose in clinical practice will depend on the achievement of metabolic outcomes and tolerance of adverse effects.
How effective is Empagliflozin for the treatment of renal disease?
Empagliflozin was associated with reduction in weight and SBP. Follow-up data published in 2016 showed that patients on empagliflozin had lower rates of new or worsening renal dysfunction compared to placebo (12.7% vs. 18.8%; P<0.001). Interestingly, the level of HbA1c reduction with empagliflozin was modest at best (0.5%).